These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38997283)

  • 1. Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade.
    von Roemeling CA; Patel JA; Carpenter SL; Yegorov O; Yang C; Bhatia A; Doonan BP; Russell R; Trivedi VS; Klippel K; Ryu DH; Grippin A; Futch HS; Ran Y; Hoang-Minh LB; Weidert FL; Golde TE; Mitchell DA
    Nat Commun; 2024 Jul; 15(1):5871. PubMed ID: 38997283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.
    von Roemeling C; Yegorov O; Yang C; Klippel K; Russell R; Trivedi V; Bhatia A; Doonan B; Carpenter S; Ryu D; Grippen A; Futch H; Ran Y; Hoang-Minh L; Weidert F; Golde T; Mitchell D
    Res Sq; 2023 Nov; ():. PubMed ID: 38014191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
    Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
    Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
    Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
    Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
    Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
    Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
    Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
    He N; Huang H; Wu S; Ji W; Tai Y; Gao R; Liu Y; Liu Y; Chen L; Zhu D; Zheng X; Jiang J
    Cancer Sci; 2024 Jul; 115(7):2196-2208. PubMed ID: 38655660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
    Pearson JRD; Puig-Saenz C; Thomas JE; Hardowar LD; Ahmad M; Wainwright LC; McVicar AM; Brentville VA; Tinsley CJ; Pockley AG; Durrant LG; McArdle SEB
    Cancer Immunol Immunother; 2024 Jul; 73(9):178. PubMed ID: 38954031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.